Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from Sandoz Group Ltd ( (CH:SDZ) ) is now available.
Sandoz has signed a global license agreement with EirGenix Inc. to commercialize a biosimilar of pertuzumab, a key oncology medicine for HER2-positive breast cancer. This strategic move aims to strengthen Sandoz’s position in the oncology sector and expand access to affordable cancer treatments, potentially impacting the USD 4.1 billion reference medicine market and aligning with the company’s goal to capitalize on the projected USD 300 billion biosimilar market over the next decade.
The most recent analyst rating on (CH:SDZ) stock is a Buy with a CHF60.00 price target. To see the full list of analyst forecasts on Sandoz Group Ltd stock, see the CH:SDZ Stock Forecast page.
More about Sandoz Group Ltd
Sandoz is a global leader in affordable medicines, headquartered in Basel, Switzerland. The company has a rich history of pioneering access to healthcare, with a diverse portfolio of approximately 1,300 products addressing a wide range of diseases. Sandoz is committed to providing substantial global healthcare savings and has a significant social impact, with net sales of USD 10.4 billion recorded in 2024.
Average Trading Volume: 703,110
Technical Sentiment Signal: Buy
Current Market Cap: CHF23.69B
For an in-depth examination of SDZ stock, go to TipRanks’ Overview page.